IP Library Granted Patent US 10,626,449
Granted Patent B2
US 10,626,449 · App. 15/412,404 · Granted Apr 21, 2020

Methods and materials for assessing allelic imbalance

Inventors: Alexander Gutin (Salt Lake City, UT); Kirsten Timms (Salt Lake City, UT); Jerry Lanchbury (Salt Lake City, UT)
Assignee: MYRIAD GENETICS, INC.
C12Q1/6827C12Q1/6858C12Q1/6874C12Q1/6883G16B30/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,626,449
App. No.
15/412,404
Granted
Apr 21, 2020
Kind
B2
Abstract

Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.

Claims (17)

1. A system for detecting copy number at a plurality of single nucleotide polymorphism loci, comprising:

(1) a sample analyzer that is configured

(a) to enrich test DNA molecules from a formalin-fixed paraffin-embedded sample, the sample comprising at least one tumor cell obtained from a patient and each test DNA molecule comprising at least one locus from the plurality of single nucleotide polymorphism loci, wherein the plurality of single nucleotide polymorphism loci comprises at least 1,000 single nucleotide polymorphism loci and wherein there is at least one single nucleotide polymorphism locus located on average every 5 Mb within each chromosome; and

(b) to sequence the test DNA molecules to produce a plurality of quantitative signals representing the alleles for each locus in the plurality of single nucleotide polymorphism loci present in the test DNA molecules; and

(2) a computer program that is configured to determine, based on the plurality of quantitative signals, the copy number at each locus in the plurality of single nucleotide polymorphism loci.

2. The system of claim 1 , wherein the plurality of single nucleotide polymorphism loci comprises at least 2,500 single nucleotide polymorphism loci.

3. The system of claim 1 , wherein the plurality of single nucleotide polymorphism loci comprises at least 5,000 single nucleotide polymorphism loci.

4. The system of claim 1 , wherein the plurality of single nucleotide polymorphism loci comprises at least 10,000 single nucleotide polymorphism loci.

5. The system of claim 1 , wherein the plurality of single nucleotide polymorphism loci comprises at least 50,000 single nucleotide polymorphism loci.

6. The system of claim 1 , wherein there is at least one single nucleotide polymorphism locus located on average every 1 Mb within each chromosome.

7. The system of claim 1 , wherein there is at least one single nucleotide polymorphism locus in the plurality of single nucleotide polymorphism loci located on average every 500 kb within each chromosome.

8. The system of claim 1 , wherein there is at least one single nucleotide polymorphism locus in the plurality of single nucleotide polymorphism loci located on average every 100 kb within each chromosome.

9. The system of claim 1 , wherein there is at least one single nucleotide polymorphism locus in the plurality of single nucleotide polymorphism loci located on average every 50 kb within each chromosome.

10. The system of claim 1 , wherein there is at least one single nucleotide polymorphism locus in the plurality of single nucleotide polymorphism loci located on average every 10 kb within each chromosome.

11. The system of claim 1 , wherein the genomic spacing of the plurality of single nucleotide polymorphism loci in the plurality of single nucleotide polymorphism loci is less than or equal to 50%.

12. The system of claim 1 , wherein the genomic spacing of the plurality of single nucleotide polymorphism loci in the plurality of single nucleotide polymorphism loci is less than or equal to 25%.

13. The system of claim 1 , wherein the genomic spacing of the plurality of single nucleotide polymorphism loci in the plurality of single nucleotide polymorphism loci is less than or equal to 10%.

Assignments (4)
SECURITY INTEREST Recorded Aug 1, 2025
From: MYRIAD GENETICS, INC.; MYRIAD GENETIC LABORATORIES, INC.; MYRIAD WOMEN’S HEALTH, INC.; ASSUREX HEALTH, INC.; GATEWAY GENOMICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT FOR SECURED PARTIES
Reel/Frame 072309/0932 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (064235/0032) Recorded Aug 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MYRIAD GENETICS, INC.; MYRIAD WOMEN’S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
Reel/Frame 072331/0215 →
PATENT SECURITY AGREEMENT Recorded Jul 7, 2023
From: MYRIAD GENETICS, INC.; MYRIAD WOMEN'S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 064235/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2021
From: GUTIN, ALEXANDER; TIMMS, KIRSTEN; LANCHBURY, JERRY
To: MYRIAD GENETICS, INC.
Reel/Frame 057864/0069 →